CorMedix (CRMD) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
Annual meeting scheduled for June 23, 2026, with voting available online, by mail, or virtually.
Shareholders are encouraged to review proxy materials and annual report before voting.
Voting matters and shareholder proposals
Election of seven directors is on the ballot.
Advisory vote on executive compensation for 2025.
Ratification of CBIZ CPAs P.C. as independent auditor for fiscal year ending December 31, 2026.
Ratification of Certificate of Designation Amendments.
Amendments to the Charter for technical changes and to update approval processes for preferred stock amendments.
Charter amendment to designate exclusive forums for certain claims.
Charter amendment to limit certain officers' personal liability for monetary damages.
Proposal to allow adjournment of the meeting if more time is needed for voting on key proposals.
Board of directors and corporate governance
Seven nominees listed for election to the board.
Board recommends voting in favor of all proposals.
Latest events from CorMedix
- Diversified portfolio, pipeline progress, and reimbursement shifts set stage for future growth.CRMD
Jefferies Global Healthcare Conference 20263 Jun 2026 - Strong growth driven by DefenCath, REZZAYO, and pipeline expansion in institutional markets.CRMD
Corporate presentation24 May 2026 - REZZAYO advances toward broader approval as DefenCath guidance and reimbursement outlook improve.CRMD
RBC Capital Markets Global Healthcare Conference 202620 May 2026 - Q1 2026 revenue and profit surged, guidance was raised, and pipeline progress accelerated.CRMD
Q1 202614 May 2026 - Proxy details robust 2025 results, major governance updates, and key proposals for shareholder approval.CRMD
Proxy filing29 Apr 2026 - Diversified portfolio and late-stage pipeline drive growth and key clinical milestones.CRMD
Investor Day 202620 Apr 2026 - Proxy outlines 2026 meeting proposals, governance updates, and strong 2025 financial results.CRMD
Proxy filing17 Apr 2026 - REZZAYO phase III data and DefenCath reimbursement reset are key near-term catalysts.CRMD
25th Annual Needham Virtual Healthcare Conference14 Apr 2026 - REZZAYO phase III data and DefenCath expansion drive growth amid a diversified, lean operation.CRMD
The Citizens Life Sciences Conference 202611 Mar 2026